pirfenidone has been researched along with Hepatitis C, Chronic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez-Álvarez, A; Arellano-Olivera, I; Armendáriz-Borunda, J; Flores-Contreras, L; Lucano-Landeros, S; Mena-Enriquez, MG; Sanchez-Parada, MG; Sandoval-Rodríguez, AS | 1 |
| Alvarez, A; Aréchiga, G; Armendáriz-Borunda, J; Berumen, J; Covarrubias, A; García, L; Islas-Carbajal, MC; Lucano, S; Meza-García, E; Rincón, AR; Salazar, A; Sandoval, AS | 1 |
2 trial(s) available for pirfenidone and Hepatitis C, Chronic
| Article | Year |
|---|---|
Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Cytokines; Fatty Liver; Female; Gene Expression; Hepatitis C, Chronic; Humans; Interleukin-6; Liver; Liver Cirrhosis; Male; Middle Aged; Pyridones; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta1; Treatment Outcome; Tumor Necrosis Factor-alpha | 2014 |
A pilot study in patients with established advanced liver fibrosis using pirfenidone.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Pyridones; Treatment Outcome | 2006 |